Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Stool samples being prepared in the lab

Fecal Transplants Show Promise as Treatment for NAFLD

Trial results could have implications for the treatment of numerous conditions including metabolic syndrome and autoimmune diseases

Lawson Health Research Institute
Published:Jun 10, 2020
|3 min read
Register for free to listen to this article
Listen with Speechify
Stool samples being prepared in the lab.
Lawson Health Research Institute

LONDON, ON, CANADA — A new study from Lawson Health Research Institute and Western University suggests that fecal transplants could be used as a treatment for non-alcoholic fatty liver disease (NAFLD). The randomized controlled trial published in the American Journal of Gastroenterology found that fecal transplants in patients with NAFLD result in a reduction in how easily pathogens and other unwanted molecules pass through the human gut and into circulation, known as intestinal permeability. The results could have implications for the treatment of numerous conditions including metabolic syndrome and autoimmune diseases.

"Intestinal permeability plays a role in the development of metabolic syndrome which is a major cause of coronary and cerebrovascular disease. It has also been associated with autoimmune diseases like multiple sclerosis (MS), rheumatoid arthritis, systemic lupus, and type 1 diabetes," explains Dr. Michael Silverman, associate scientist at Lawson and professor at Western's Schulich School of Medicine & Dentistry.

Many NAFLD patients have increased intestinal permeability which triggers inflammation, increased fat in the liver, insulin resistance, and elevated levels of triglycerides in the blood. The human microbiome—the diverse collection of microbes in our body—is thought to play a role. Previous studies have shown differences between the gut microbiome of NAFLD patients compared to healthy individuals.

Lawson Health Research Institute

"Our team wondered whether we could change the gut microbiome of NAFLD patients to reduce intestinal permeability," says Dr. Jeremy Burton, Lawson scientist and associate professor at Schulich Medicine & Dentistry.

The trial included 21 NAFLD patients from London Health Sciences Centre (LHSC) and St. Joseph's Health Care London. Patients were randomized to receive a fecal transplant using stool from a healthy donor or a placebo (the patient's own stool). Fecal material was delivered to the small intestine using endoscopy. Patients were followed for six months to assess changes to their gut microbiome, intestinal permeability, percentage of liver fat, and insulin resistance.

Dr. Laura Craven.

While the researchers found no changes in percentage of liver fat or insulin resistance, they observed significant reduction in intestinal permeability in those patients who had elevated intestinal permeability at the study's start (seven patients in total). They also observed changes to the gut microbiome in all patients who received a fecal transplant from a healthy donor.

"Our study demonstrates that intestinal permeability can be improved through fecal transplant from a healthy donor," says Dr. Laura Craven, a recent PhD graduate from Schulich Medicine & Dentistry and first author on the published study. "This suggests that fecal transplant could be used as an early intervention in the treatment of NAFLD to reduce intestinal permeability and prevent inflammation"

Related Article: Fecal Transplantation to Treat Patients with Parkinson's Disease: Hope or Hype?

"Our findings have implications for other conditions too," adds Dr. Silverman, who is also chair/chief of infectious diseases at Western, LHSC, and St. Joseph's. "Changing the gut microbiome could hold promise in preventing and treating metabolic syndrome and autoimmune diseases associated with increased gut permeability."

The team hopes to next conduct a large multi-center trial to further investigate FMT as an intervention for NAFLD and as a therapy to reduce intestinal permeability.

Dr. Michael Silverman (left) and Dr. Jeremy Burton (right),

NAFLD is an obesity-related disorder and is the second-leading cause of liver transplant in North America. While reversible if treated early, its progression can lead to liver failure or cancer. Current therapies are not overly effective and the prevalence of NAFLD is increasing.

Silverman is a pioneer in the field of fecal transplants, including their use as a treatment for Clostridioides difficile (C. diff). He is involved in multiple studies examining the potential of fecal transplants as treatments or supportive therapies for numerous conditions including multiple sclerosis (MS) and different types of cancer.

"In order to conduct this research, we need stool donors," notes Silverman. "By donating your poop, you can help us assess the value of fecal transplants to treat a variety of diseases."

The team is in need of young, healthy stool donors for fecal transplants. All donors are required to go through a screening process. Those interested in becoming a stool donor can contact Dr. Seema Nair Parvathy, research coordinator, Fecal Transplant Program, at 519-646-6100 ext. 61726.

- This press release was originally published on the Lawson Health Research Institute website